Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody targeting IL-17A, in healthy subjects and patients with moderate to severe plaque psoriasis (PsO)

Congjun Jiang,Yu Du,Xiaoyan Liu,Jingjing Wang,Cuizhu Ge,Jingyue Xu,Shuoxiong Wang,Benke Li,Gege Zhu,Wanlu Zhang,Qiaoxiao Qian,Chi Ma,Xiangyang Zhu,Yifan Zhan,Yongmin Yang
DOI: https://doi.org/10.1093/bjd/ljad315
IF: 11.113
2023-09-05
British Journal of Dermatology
Abstract:Abstract Background Several IL-17 inhibitors have been approved for the treatment of moderate to severe plaque psoriasis. There is still a scope for the development of the affordable treatments of psoriasis. Objectives To assess the safety, tolerability and pharmacokinetics (PK) of HB0017, a humanized monoclonal antibody targeting IL-17A, in healthy subjects and patients with moderate to severe plaque psoriasis; to assess the efficacy of HB0017 in moderate to severe plaque psoriasis patients in the Phase Ib study. Methods The Phase Ia study was a randomized, double-blind, placebo-controlled, dose-escalation study in enrolled healthy subjects. Each cohort of 10 volunteers was randomly assigned to receive either a single dose of HB0017 (50 mg, 150 mg, 300 mg or 450 mg) or the matching placebo at a ratio of 4:1. The Phase Ib study was a randomized, double-blind, placebo-controlled, dose-escalation study in enrolled patients with moderate to severe plaque psoriasis. Each cohort of 10 patients was randomly assigned to receive either multiple doses of HB0017 (150 mg, 300 mg or 450 mg) or the matching placebo at a ratio of 4:1. Results HB0017 demonstrated dose-proportional linear PK and was tolerated across the dose range assessed. In the Phase Ia and Phase Ib studies, subjects in both HB0017 and placebo groups experienced TEAEs (68.8% vs. 87.5%, 95.8% vs. 100.0%, respectively). HB0017 demonstrated clinically meaningful effects in patients with moderate to severe plaque psoriasis. PASI75, PASI90, sPGA0/1 responses were 100.0% for the HB0017 300 mg group, with maximal improvements (100% or near 100% reductions from baseline) in PASI score were observed at week 12, while the duration of effect was evident up to week 20. There was no clinical response in all placebo group subjects in the Phase Ib study. Conclusions Overall, HB0017 showed acceptable safety and tolerability in both healthy subjects and patients with moderate to severe plaque psoriasis. An encouraging signal of efficacy with a longer half-life provides potential as an additional agent to the currently available range of biologics targeting IL-17A. Clinical Trial identifier NCT04505033, NCT05442788
dermatology
What problem does this paper attempt to address?